A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Recruiting Phase 2 Interventional Study
Myeloma Myeloma Multiple
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
100 (estimated)
Sponsor
AHS Cancer Control Alberta · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma, * Stable clinical status as deemed by responsible investigator, * Personally (or caregiver) willing and deemed capable to self-administer with teaching, * Previously received more than 4 injection…
Contacts

Jason Tay, MD

587-231-5437

Jason.Tay@ahs.ca

CONTACT

Amy Abel

Amy.Abel@ahs.ca

CONTACT